FI931765A7 - Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt - Google Patents

Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt Download PDF

Info

Publication number
FI931765A7
FI931765A7 FI931765A FI931765A FI931765A7 FI 931765 A7 FI931765 A7 FI 931765A7 FI 931765 A FI931765 A FI 931765A FI 931765 A FI931765 A FI 931765A FI 931765 A7 FI931765 A7 FI 931765A7
Authority
FI
Finland
Prior art keywords
preparation
treatment
benign prostatic
prostatic hyperplasia
steroid derivatives
Prior art date
Application number
FI931765A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI931765L (fi
FI931765A0 (fi
Inventor
Hiroyoshi Horikoshi
Koichi Kojima
Hitoshi Kurata
Koki Ishibashi
Takakazu Hamada
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of FI931765A0 publication Critical patent/FI931765A0/fi
Publication of FI931765L publication Critical patent/FI931765L/fi
Publication of FI931765A7 publication Critical patent/FI931765A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI931765A 1992-04-20 1993-04-19 Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt FI931765A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9981692 1992-04-20
JP32804392 1992-12-08

Publications (3)

Publication Number Publication Date
FI931765A0 FI931765A0 (fi) 1993-04-19
FI931765L FI931765L (fi) 1993-10-21
FI931765A7 true FI931765A7 (fi) 1993-10-21

Family

ID=26440917

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931765A FI931765A7 (fi) 1992-04-20 1993-04-19 Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt

Country Status (24)

Country Link
US (3) US5536714A (cg-RX-API-DMAC7.html)
EP (2) EP0567271B1 (cg-RX-API-DMAC7.html)
JP (1) JP2514778B2 (cg-RX-API-DMAC7.html)
KR (1) KR0146680B1 (cg-RX-API-DMAC7.html)
CN (2) CN1041095C (cg-RX-API-DMAC7.html)
AT (1) ATE154937T1 (cg-RX-API-DMAC7.html)
AU (1) AU656852B2 (cg-RX-API-DMAC7.html)
CA (1) CA2094300C (cg-RX-API-DMAC7.html)
CZ (2) CZ283791B6 (cg-RX-API-DMAC7.html)
DE (1) DE69311837T2 (cg-RX-API-DMAC7.html)
DK (1) DK0567271T3 (cg-RX-API-DMAC7.html)
ES (1) ES2105108T3 (cg-RX-API-DMAC7.html)
FI (1) FI931765A7 (cg-RX-API-DMAC7.html)
GR (1) GR3024896T3 (cg-RX-API-DMAC7.html)
HU (1) HU219579B (cg-RX-API-DMAC7.html)
ID (1) ID18576A (cg-RX-API-DMAC7.html)
IL (1) IL105478A (cg-RX-API-DMAC7.html)
MX (1) MX9302300A (cg-RX-API-DMAC7.html)
NO (1) NO304891B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ247449A (cg-RX-API-DMAC7.html)
PH (1) PH31052A (cg-RX-API-DMAC7.html)
RU (2) RU2114861C1 (cg-RX-API-DMAC7.html)
TW (2) TW238312B (cg-RX-API-DMAC7.html)
ZA (1) ZA932732B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1259419B (it) * 1991-05-24 1996-03-18 Erba Carlo Spa Steroidi 3-carbossi 17b - sostituiti insaturi utili come inibitori della testosterone 5 a reduttasi
SK129294A3 (en) * 1992-04-30 1995-07-11 Smithkline Beecham Corp 17-alpha and 17-beta-substituted estra-1,3,5(10)-triene-3- -carboxylic acid
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors
GB9224148D0 (en) * 1992-11-18 1993-01-06 Smithkline Beecham Corp Compounds
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
EP0717618B1 (en) * 1993-09-03 2002-11-06 Smithkline Beecham Corporation Stabilized tablet formulation
GB9324371D0 (en) * 1993-11-26 1994-01-12 Erba Carlo Spa Side chain fluoro substituted 3-carboxysteroids
GB9411103D0 (en) * 1994-06-03 1994-07-27 Smithkline Beecham Corp Compounds
GB9415183D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 3-carboxysteroids with a fluorinated side-chain
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
DE69942578D1 (de) 1998-05-22 2010-08-26 Univ R Bifunktionelle moleküle sowie darauf basierende therapien.
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
AU2002331916B2 (en) * 2001-10-03 2008-07-24 Merck Sharp & Dohme Corp. Androstane 17-beta-carboxamides as androgen receptor modulators
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
EP1587574A4 (en) * 2001-12-21 2009-03-18 Rhode Island Hospital SELECTIVE 11b-HSD HEMMER AND METHOD OF USE THEREOF
WO2004097002A2 (en) * 2003-04-29 2004-11-11 The Miriam Hospital SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
CA2789097C (en) 2005-04-28 2017-02-21 Proteus Digital Health, Inc. Pharma-informatics system
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
US7604386B2 (en) * 2005-11-18 2009-10-20 Federal-Mogul World Wide, Inc Lamp assembly having a socket made from high temperature plastic
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
JP2012526144A (ja) 2009-05-06 2012-10-25 ラボラトリー スキン ケア インコーポレイテッド 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法
WO2011004242A2 (en) * 2009-07-09 2011-01-13 Aurobindo Pharma Limited An improved process for the preparation of dutasteride
CN111362999B (zh) * 2020-03-16 2022-03-29 江苏联环药业股份有限公司 一种爱普列特杂质及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5196411A (en) * 1991-08-16 1993-03-23 Merck & Co., Inc. 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors

Also Published As

Publication number Publication date
CN1195666A (zh) 1998-10-14
DE69311837T2 (de) 1998-02-12
US5717088A (en) 1998-02-10
US5760025A (en) 1998-06-02
MX9302300A (es) 1994-03-31
FI931765L (fi) 1993-10-21
JP2514778B2 (ja) 1996-07-10
NZ247449A (en) 1995-02-24
NO931401L (no) 1993-10-21
CN1083070A (zh) 1994-03-02
GR3024896T3 (en) 1998-01-30
CA2094300A1 (en) 1993-10-21
KR0146680B1 (ko) 1998-08-01
EP0725074A2 (en) 1996-08-07
CA2094300C (en) 2003-01-28
CZ284206B6 (cs) 1998-09-16
TW238312B (cg-RX-API-DMAC7.html) 1995-01-11
RU2097387C1 (ru) 1997-11-27
CZ283791B6 (cs) 1998-06-17
HUT64558A (en) 1994-01-28
HK1000303A1 (en) 1998-02-20
AU3698493A (en) 1993-10-21
DE69311837D1 (de) 1997-08-07
ES2105108T3 (es) 1997-10-16
KR930021654A (ko) 1993-11-22
NO931401D0 (no) 1993-04-16
PH31052A (en) 1998-02-03
HU9301155D0 (en) 1993-07-28
RU95101838A (ru) 1997-01-10
TW401420B (en) 2000-08-11
FI931765A0 (fi) 1993-04-19
CZ90097A3 (cs) 1998-07-15
AU656852B2 (en) 1995-02-16
IL105478A (en) 1998-03-10
CN1041095C (zh) 1998-12-09
EP0567271A2 (en) 1993-10-27
ZA932732B (en) 1993-10-28
ID18576A (id) 1998-04-23
EP0567271A3 (en) 1994-11-23
JPH06279487A (ja) 1994-10-04
RU2114861C1 (ru) 1998-07-10
EP0567271B1 (en) 1997-07-02
IL105478A0 (en) 1993-08-18
US5536714A (en) 1996-07-16
DK0567271T3 (da) 1998-02-16
CZ67893A3 (en) 1994-01-19
EP0725074A3 (en) 1996-11-20
ATE154937T1 (de) 1997-07-15
NO304891B1 (no) 1999-03-01
HU219579B (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
FI931765A7 (fi) Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt
NO993396L (no) Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
BR9608651A (pt) Método para o tratamento de hiperplasia prostática benigna com terapia térmica
IL101243A0 (en) Pharmaceutical compositions for treatment of benign prostatic hyperplasia
ITMI920528A0 (it) 14-beta idrossi-10-de acetil-baccatina iii, suoi derivati, loro preparazione ed impiego terapeutico
NO914036D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater
PL315941A1 (en) 4-heterocyclic substituted derivatives of quinazoline, methods of obtaining them and their application as anticarcinogenic agents
IL101574A0 (en) Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia
BR9306619A (pt) Glicosídeos esteroidais para o tratamento da hipercolesterolemia
NO900613D0 (no) Fremgangsmaate for fremstilling av aktiverte chitosaner oganvendelse ved fremstilling av chitosanderivater.
NO911934L (no) Fremgangsmaate for fremstilling av bicykliske 1-aza-cykloalkaner.
NO904921D0 (no) Fremgangsmaate til fremstilling av modifiserte gangliosider og deres funksjonelle derivater.
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
DE69302863D1 (de) Wässrige Beschichtungszusammensetzung und diese verwendendes Beschichtungsverfahren
NO992504L (no) Sammensetninger for behandling av jord, fremgangsmÕte for fremstilling derav, samt anvendelse
EP0369216A3 (en) Pharmaceutical preparation based on ester derivatives of hecogenine, and their use in treating benign prostatic hyperplasia
FI931701A7 (fi) Rasvan muodostumista ehkäisevän tekijän johdannaiset, niiden valmistus ja käyttö
NO892505D0 (no) Behandling av vandige dispersjoner.
NO891985D0 (no) Fremgangsmaate for fremstilling av dibenzotiofen- og tioxanten-derivater.
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
FI945562L (fi) 1,3,4-oksadiatsol-2(3H)-onijohdannaiset, niiden valmistus ja terapeuttinen käyttö
NO913187L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tricykliske derivater.
AU5457694A (en) Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
NO975838D0 (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi
ITBO920160A0 (it) Composizione e procedimento per il trattamento dei tessuti